JP2022506761A5 - - Google Patents

Info

Publication number
JP2022506761A5
JP2022506761A5 JP2021524345A JP2021524345A JP2022506761A5 JP 2022506761 A5 JP2022506761 A5 JP 2022506761A5 JP 2021524345 A JP2021524345 A JP 2021524345A JP 2021524345 A JP2021524345 A JP 2021524345A JP 2022506761 A5 JP2022506761 A5 JP 2022506761A5
Authority
JP
Japan
Prior art keywords
antibody construct
item
seq
heavy chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058648 external-priority patent/WO2020092427A1/en
Publication of JP2022506761A publication Critical patent/JP2022506761A/ja
Publication of JP2022506761A5 publication Critical patent/JP2022506761A5/ja
Priority to JP2024144789A priority Critical patent/JP2024170456A/ja
Pending legal-status Critical Current

Links

JP2021524345A 2018-10-29 2019-10-29 IgA抗体構築物を含む組成物および方法 Pending JP2022506761A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024144789A JP2024170456A (ja) 2018-10-29 2024-08-26 IgA抗体構築物を含む組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18203183 2018-10-29
EP18203183.1 2018-10-29
US201862752641P 2018-10-30 2018-10-30
US62/752,641 2018-10-30
PCT/US2019/058648 WO2020092427A1 (en) 2018-10-29 2019-10-29 COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024144789A Division JP2024170456A (ja) 2018-10-29 2024-08-26 IgA抗体構築物を含む組成物および方法

Publications (2)

Publication Number Publication Date
JP2022506761A JP2022506761A (ja) 2022-01-17
JP2022506761A5 true JP2022506761A5 (cg-RX-API-DMAC7.html) 2022-10-31

Family

ID=70462698

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524345A Pending JP2022506761A (ja) 2018-10-29 2019-10-29 IgA抗体構築物を含む組成物および方法
JP2024144789A Pending JP2024170456A (ja) 2018-10-29 2024-08-26 IgA抗体構築物を含む組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024144789A Pending JP2024170456A (ja) 2018-10-29 2024-08-26 IgA抗体構築物を含む組成物および方法

Country Status (9)

Country Link
US (1) US20210332131A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873942A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022506761A (cg-RX-API-DMAC7.html)
KR (1) KR20210096612A (cg-RX-API-DMAC7.html)
CN (1) CN113260632A (cg-RX-API-DMAC7.html)
AU (1) AU2019369397B2 (cg-RX-API-DMAC7.html)
CA (1) CA3118312A1 (cg-RX-API-DMAC7.html)
GB (1) GB2596411B (cg-RX-API-DMAC7.html)
WO (1) WO2020092427A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3131705A1 (en) * 2019-03-27 2020-10-01 Umc Utrecht Holding B.V. Engineered iga antibodies and methods of use
CA3187850A1 (en) 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
JP2023546679A (ja) * 2020-10-22 2023-11-07 アクティニウム ファーマシューティカルズ インコーポレイテッド がん治療における放射免疫療法とcd47遮断の併用
CN116829698A (zh) * 2020-12-07 2023-09-29 加利福尼亚大学董事会 通过SIRP-α衔接体的先天免疫细胞沉默
CN116731161A (zh) * 2021-09-18 2023-09-12 南开大学 工程化IgG和IgA嵌合的“四叶草型X抗体”
EP4475886A4 (en) * 2022-02-09 2026-03-18 Exelixis Inc MULTI-SPECIFIC LIAISON AGENTS AND THEIR USES

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226878D0 (en) * 2002-11-18 2002-12-24 Univ Warwick Antibodies
HUE038955T2 (hu) * 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
SI2477648T1 (sl) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
WO2013087914A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
RU2693078C2 (ru) * 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
US20140213771A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Multi-specific binding proteins
EP2970485A1 (en) * 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP3188758B1 (en) * 2014-08-08 2023-10-04 The Board of Trustees of the Leland Stanford Junior University Sirp alpha-antibody fusion proteins
ES2751915T5 (es) * 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa
US9650441B2 (en) * 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
CN107459579B (zh) * 2016-06-01 2021-09-24 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
CA3035427A1 (en) * 2016-09-01 2018-03-08 Umc Utrecht Holding B.V. Cd20 antibodies
KR102607101B1 (ko) * 2017-01-26 2023-11-29 제트엘아이피 홀딩 리미티드 Cd47 항원 결합 유닛 및 그것의 사용
WO2019022600A1 (en) * 2017-07-24 2019-01-31 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47
AU2018314765C1 (en) * 2017-08-08 2025-11-20 Bruker Spatial Biology, Inc. Obinutuzumab treatment of a DLBCL patient subgroup

Similar Documents

Publication Publication Date Title
CN102741282B (zh) 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途
CN110914306B (zh) 检查点抑制物双特异性抗体
JP6359372B2 (ja) DARPinを含む二重特異キメラ蛋白質
JP2021508469A5 (cg-RX-API-DMAC7.html)
JP7611171B2 (ja) 抗ror1/抗cd3二重特異性結合分子
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2021524268A5 (cg-RX-API-DMAC7.html)
JP2018503380A5 (cg-RX-API-DMAC7.html)
JP2020504723A5 (cg-RX-API-DMAC7.html)
RU2019123613A (ru) Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9
US12168690B2 (en) Anti-EGFR/anti-4-1BB bispecific antibody
JP2021510521A5 (cg-RX-API-DMAC7.html)
JP2010536378A5 (cg-RX-API-DMAC7.html)
JP2025503322A5 (cg-RX-API-DMAC7.html)
JP2018502050A5 (cg-RX-API-DMAC7.html)
FI3941946T3 (fi) Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2021508707A5 (cg-RX-API-DMAC7.html)
JP2010509931A5 (cg-RX-API-DMAC7.html)
WO2012057288A1 (ja) 新規抗dr5抗体
JP2022545741A5 (cg-RX-API-DMAC7.html)
GB2596411A (en) Compositions and methods comprising IgA antibody constructs
CA3208455A1 (en) Novel anti-gremlin1 antibodies
JP2023549316A5 (cg-RX-API-DMAC7.html)